While well established in other tumor types, such as breast cancer and gastric cancer, HER2 overexpression or amplification has recently emerged as an important and actionable oncogenic driver in CRC that can be screened for and identified with diagnostic tools, and then targeted using biomarker-directed therapy. The gene discussed is ERBB2; the disease is neoplasm.